Questionnements éthiques en ORL pendant la pandémie COVID-19 : étude qualitative de témoignages

François Simon, Cécile Parietti‐Winkler(Université de Lorraine), B. Barry(Assistance Publique – Hôpitaux de Paris), Natacha Heutte(Centre François Baclesse), Nicolas Leboulanger(Hôpital Necker-Enfants Malades), E. Babin, L. Plisson(Centre Hospitalier Universitaire de Caen Normandie)

Éthique & Santé

April 21, 2021

10.1016/j.etiqe.2021.04.006

Cited by 1

Related Papers

Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study

|Journal of Clinical Oncology|2013|418

Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma

|International Journal of Pediatric Otorhinolaryngology|2009|235

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

|The Lancet Oncology|2021|231

Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of age

|British Journal of Haematology|2016|130

Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience

|International Journal of Pediatric Otorhinolaryngology|2010|110